Rodríguez-Rodríguez L, Sancho-Torres I, Mesonero C, Gibbon D G, Shih W J, Zotalis G
The Cancer Institute of New Jersey, Division of Gynecologic Oncology, UMDNJ/Robert Wood Johnson Medical School, Department of Obstetrics and Gynecology, New Brunswick, NJ 08901, USA.
Med Oncol. 2003;20(3):255-63. doi: 10.1385/MO:20:3:255.
CD44 is a cell surface receptor implicated in cancer progression and metastases. Malignant tumors may show a loss of CD44 splice control mechanisms. We investigated the role of CD44 splice variant expression in ovarian tumors and metastases, and its association with survival.
We tested CD44 expression in 142 cases of epithelial carcinoma of the ovary and 265 metastatic sites by immunohistochemistry.
Survival analysis showed that the expression of CD44s, CD44-v4, -v5, -v6, -v9, and -v10 are significant predictors for survival in univariate analysis. After stage, the expression of CD44-v10 in metastases was the strongest predictor of decreased survival in multivariate analysis (p = 0.0009). Conversely, CD44-v10 expression in the primary tumor was an independent predictor of improved survival in multivariate analysis (p = 0.0002). The expression of CD44s in the tumor/stroma interface of the primary tumor was associated with improved survival (p < 0.0001).
CD44 variant expression is a molecular prognostic maker for epithelial ovarian carcinomas. CD44-v10 expression is an independent prognostic indicator and the site of expression determines a positive or negative influence in survival. Our results also indicate that CD44 may be involved in important tumor/stroma interactions.
CD44是一种与癌症进展和转移相关的细胞表面受体。恶性肿瘤可能表现出CD44剪接控制机制的缺失。我们研究了CD44剪接变体表达在卵巢肿瘤和转移中的作用及其与生存的关系。
我们通过免疫组织化学检测了142例卵巢上皮癌和265个转移部位的CD44表达。
生存分析表明，在单因素分析中，CD44s、CD44-v4、-v5、-v6、-v9和-v10的表达是生存的重要预测指标。在分期之后，转移灶中CD44-v10的表达在多因素分析中是生存降低的最强预测指标（p = 0.0009）。相反，原发性肿瘤中CD44-v10的表达在多因素分析中是生存改善的独立预测指标（p = 0.0002）。原发性肿瘤肿瘤/基质界面中CD44s的表达与生存改善相关（p < 0.0001）。
CD44变体表达是上皮性卵巢癌的分子预后标志物。CD44-v10表达是一个独立的预后指标，其表达部位决定了对生存的正向或负向影响。我们的结果还表明，CD44可能参与重要的肿瘤/基质相互作用。
